Growth Metrics

Eli Lilly (LLY) Cash from Operations Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 45.52%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -8.27%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -2.98%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 43.03%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 27.18%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 13.41%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 29.22%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -28.10%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 45.52%
Dec 31, 2025 24.71%
Sep 30, 2025 58.56%
Jun 30, 2025 37.65%
Mar 31, 2025 -12.92%
Dec 31, 2024 3.03%
Sep 30, 2024 31.53%
Jun 30, 2024 -6.18%
Mar 31, 2024 -11.77%
Dec 31, 2023 -29.50%
Sep 30, 2023 6.62%
Jun 30, 2023 -36.73%
Mar 31, 2023 65.41%
Dec 31, 2022 -5.40%
Sep 30, 2022 13.65%
Jun 30, 2022 4.01%
Mar 31, 2022 100.87%
Dec 31, 2021 16.01%
Sep 30, 2021 -8.39%
Jun 30, 2021 5.37%
Mar 31, 2021 57.25%
Dec 31, 2020 1.35%
Sep 30, 2020 -1.34%
Jun 30, 2020 14.76%
Mar 31, 2020 4.01%
Dec 31, 2019 -0.72%
Sep 30, 2019 -3.14%
Jun 30, 2019 -9.14%
Mar 31, 2019 50.68%
Dec 31, 2018 13.30%
Sep 30, 2018 24.30%
Jun 30, 2018 16.95%
Mar 31, 2018 92.63%
Dec 31, 2017 6.56%
Sep 30, 2017 3.61%
Jun 30, 2017 16.14%
Mar 31, 2017 7.67%
Dec 31, 2016 5.13%
Sep 30, 2016 -5.86%
Jun 30, 2016 -5.04%
Mar 31, 2016 -37.11%
Dec 31, 2015 -14.65%
Sep 30, 2015 -10.57%
Jun 30, 2015 -10.11%
Mar 31, 2015 -28.05%
Dec 31, 2014 -9.51%
Sep 30, 2014 -6.56%
Jun 30, 2014 -19.76%
Mar 31, 2014 -38.60%
Dec 31, 2013 -8.15%
Sep 30, 2013 4.22%
Jun 30, 2013 -5.03%
Mar 31, 2013 -26.56%
Dec 31, 2012 -7.42%
Sep 30, 2012 5.75%
Jun 30, 2012 12.25%
Mar 31, 2012 113.26%